# Proxalutamide Treatment for COVID-19 Female Outpatients

> **NCT04853134** · PHASE3 · WITHDRAWN · sponsor: **Applied Biology, Inc.**

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Proxalutamide
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04853134
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was combined with another study
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853134, "Proxalutamide Treatment for COVID-19 Female Outpatients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04853134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*